The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
about
Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate VaccinationThe inhibition of indoleamine 2, 3-dioxygenase 1 by connexin 43.Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.Metabolomics and Metabolic Reprogramming in Kidney Cancer.Tumor-Associated Fibroblasts and Microvessels Contribute to the Expression of Immunosuppressive Factor Indoleamine 2, 3-Dioxygenase in Human Esophageal Cancers.Small Molecules Drive Big Improvements in Immuno-Oncology Therapies.Description of CD8 Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and CancerEmerging Therapies in the Management of Advanced-Stage Gastric CancerUpdates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human CancersTranslating Metabolic Reprogramming into New Targets for Kidney CancerQuick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancerTargeting the IDO1 pathway in cancer: from bench to bedside
P2860
Q28074536-55892813-7CA4-4CAB-9EF9-B68F263FEB7EQ47124037-95BEBE5A-4793-4D76-9BF5-72519919BEC3Q48306002-FC07C1C9-2285-4575-94F1-00A4DE6A92F9Q52618376-069B1143-A83E-4972-98D7-D8FAE93E75CEQ52873461-B2FEDEA3-A4A4-4C1A-A7B6-6F40A3EECEF9Q53047113-88A6EB01-8978-4408-AE2D-4F35F14DA684Q56890349-6FB74EB2-0CCF-4B5F-8234-BD8E84854815Q57111080-37EB84C1-6674-4A18-AE75-B05A9A00AABCQ58584052-B092D36C-0596-4ED5-A2C7-CB3EBC7FF8E6Q58585088-EE3B28D6-B6E4-4E04-BD25-8A503251ED07Q58725140-DFC5A978-0704-47E7-9468-DC08F1B356EFQ58803138-0F25B86E-CDDB-4392-B49C-ECEAC47C6B49
P2860
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The IDO1 selective inhibitor e ...... tumor antigen-specific T cells
@ast
The IDO1 selective inhibitor e ...... tumor antigen-specific T cells
@en
The IDO1 selective inhibitor e ...... tumor antigen-specific T cells
@nl
type
label
The IDO1 selective inhibitor e ...... tumor antigen-specific T cells
@ast
The IDO1 selective inhibitor e ...... tumor antigen-specific T cells
@en
The IDO1 selective inhibitor e ...... tumor antigen-specific T cells
@nl
prefLabel
The IDO1 selective inhibitor e ...... tumor antigen-specific T cells
@ast
The IDO1 selective inhibitor e ...... tumor antigen-specific T cells
@en
The IDO1 selective inhibitor e ...... tumor antigen-specific T cells
@nl
P2093
P2860
P3181
P356
P1433
P1476
The IDO1 selective inhibitor e ...... tumor antigen-specific T cells
@en
P2093
Anna R Kwilas
Caroline Jochems
Christopher R Heery
Italia Grenga
James L Gulley
James W Hodge
Jeffrey Schlom
Kwong Y Tsang
Lauren M Lepone
Martin W Brechbiel
P2860
P304
37762-37772
P3181
P356
10.18632/ONCOTARGET.9326
P407
P577
2016-06-01T00:00:00Z